Experian Health’s 2025 State of Claims survey shows rising denial rates, data errors, and low artificial intelligence adoption despite providers’ belief in its potential.
Christopher Gold, DO
Advertisement
Articles by Christopher Gold, DO
As drug denials increase, experts discuss the importance of optimizing data to keep up with these changes and implementing artificial intelligence (AI) to reduce the burden on providers and ensure patient access to care and treatment.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Guselkumab for Pediatric Plaque Psoriasis, Active Psoriatic Arthritis
2
New Insight on Biologic Initiation Patterns for Treating Severe Asthma
3
Nerandomilast a "No-Brainer" for First-Line Pulmonary Fibrosis Therapy: Justin M. Oldham, MD, PhD, MS
4
Predicting Patient Response in the Move Toward Precision Medicine in Myasthenia Gravis
5
